文献速递牙周病

噬菌体控制牙周致病菌:系统综述

Bacteriophages for periodontal pathogens control: A systematic review.
PubMed 文献 · J Dent · 2025-07-09

本系统综述旨在分析噬菌体疗法控制牙周致病菌生长的有效性。结论认为噬菌体疗法在体外有效,可能成为牙周炎尤其耐药病例的潜在策略,但需在多物种生物膜和临床环境中进一步验证。

要点

  • 噬菌体疗法在体外可有效控制牙周致病菌生长。
  • 需在多物种生物膜和临床环境中进一步验证。

核心结论

  • 噬菌体疗法在体外有效控制牙周致病菌,可能成为牙周炎尤其抗微生物药物耐药病例的潜在策略。

研究设计与样本

  • 系统综述,方案注册于PROSPERO(CRD42023479696),遵循PRISMA指南,采用PICOS框架。
  • 纳入评估噬菌体用于控制牙周致病菌的体外研究,采用RoBDEMAT评估偏倚风险,GRADE评估证据确定性。
  • 共纳入8项研究。

主要发现

  • 所有纳入研究均显示噬菌体有效控制牙周致病菌生长。
  • 分析的4种牙周致病菌包括:Aggregatibacter actinomycetemcomitans(n=3)、Fusobacterium nucleatum(n=3)、Streptococcus gordonii(n=2)和Porphyromonas gingivalis(n=1)。
  • 评估细菌生长的主要方法为光密度测量(n=7)和菌落形成单位(CFU)(n=3)。

临床怎么用

  • 噬菌体疗法可作为牙周病管理的一种创新靶向替代方案,尤其针对抗微生物药物耐药病例。

局限性

  • 需在更复杂的模型如多物种生物膜和临床环境中进一步研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Faced with the growing challenge of bacterial resistance to antibiotics, bacteriophages emerge as a promising alternative due to their specificity and ability to lyse specific bacteria. This systematic review aims to analyze the efficacy of bacteriophage therapy in controlling the growth of periodontal pathogen. DATA SOURCES: The protocol was registered in PROSPERO (CRD42023479696). The review followed PRISMA guidelines, utilizing a PICOS framework. Studies were identified through searches in seven databases (Embase, LILACS, PubMed, SCOPUS, Web of Science, Google Scholar and ProQuest) up to November 2024. STUDY SELECTION: In vitro studies were evaluating the use of bacteriophages for this purpose were considered eligible. References were selected through a two-phase process. RoBDEMAT was used to assess the risk of bias. The certainty of the cumulative evidence was evaluated using the GRADE criteria. RESULTS: Eight studies were included, all demonstrating bacteriophages are effective in controlling periodontopathogenic bacteria growth. Four periodontal pathogen bacteria were analyzed, including Aggregatibacter actinomycetemcomitans (n = 3), Fusobacterium nucleatum (n = 3), Streptococcus gordonii (n = 2), and Porphyromonas gingivalis (n = 1). Eleven different types of bacteriophages were described, including: S1249 (n = 2), ΦSG005 (n = 2), JD-Fnp1 (n = 1), d-Fnp2 (n = 1), JD-Fnp3 (n = 1), JD-Fnp4 (n = 1), JD-Fnp5 (n = 1), FNU1 (n = 1), Aabφ01 (n = 1), Aabφ01-1 (n = 1), and Fnp02 (n = 1). The predominant method for evaluating bacterial growth was optical density measurement (n = 7) colony-forming unit (CFU) (n = 3). CONCLUSION: Bacteriophage therapy effectively controls periodontal pathogenic bacteria in vitro, offering a possibility promising strategy for treating periodontitis, especially in antimicrobial-resistant cases. However, further research is needed to validate these findings in more complex models, such as multispecies biofilms and clinical settings. CLINICAL SIGNIFICANCE: This study underscores the potential of bacteriophages as an innovative and targeted alternative for managing periodontal disease.

来源:J Dent,查看原文。版权归原作者所有。

引用

  1. Dallepiane FG, Nogueira MAC, Menezes Dos Anjos L, et al. Bacteriophages for periodontal pathogens control: A systematic review. J Dent. 2025. PMID: 40645364. doi:10.1016/j.jdent.2025.105960

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。